Skip to content

Dose-Response Interaction of Metoprolol and Sufentanil for Attenuating Hemodynamic Responses in Tracheal Intubation

Dose-Response Interaction of Metoprolol and Sufentanil for Attenuating Hemodynamic Responses in Tracheal Intubation: Prospective Randomized Double-blind Study

Status
Not yet recruiting
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07597564
Enrollment
900
Registered
2026-05-19
Start date
2026-06-22
Completion date
2027-05-22
Last updated
2026-05-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

General Anesthesia; Tracheal Intubation

Brief summary

This randomized, double-blind, controlled clinical study will evaluate the effects of different dose combinations of intravenous metoprolol and sufentanil on cardiovascular responses during oral endotracheal intubation under general anesthesia. Endotracheal intubation may cause transient increases in heart rate and blood pressure due to sympathetic stimulation. This study aims to determine whether metoprolol, in combination with different doses of sufentanil, can improve hemodynamic stability during and after intubation. A total of 900 adult patients aged 18 to 65 years with American Society of Anesthesiologists physical status I or II who are scheduled for elective non-cardiac surgery under general anesthesia with endotracheal intubation will be enrolled. Participants will be randomly assigned to one of 30 groups according to the combination of metoprolol dose and sufentanil dose. Metoprolol doses include 0, 0.1, 0.2, 0.3, 0.4, and 0.5 mg/kg, and sufentanil doses include 0.1, 0.2, 0.3, 0.4, and 0.5 mcg/kg. All participants will receive standardized anesthetic induction and maintenance. Hemodynamic changes will be observed for 10 minutes after intubation. The main outcome is the success rate of hemodynamic stability within 0 to 10 minutes after intubation. Secondary outcomes include the incidence of hypotension, hypertension, bradycardia, and tachycardia.

Interventions

Metoprolol will be administered intravenously before anesthetic induction at the assigned dose of 0, 0.1, 0.2, 0.3, 0.4, or 0.5 mg/kg. The study drug will be given through a dedicated intravenous catheter, and each participant will receive the dose according to the randomized treatment arm.

DRUGSufentanil

Sufentanil will be administered intravenously during anesthetic induction at the assigned dose of 0.1, 0.2, 0.3, 0.4, or 0.5 mcg/kg. Each participant will receive sufentanil in combination with the assigned metoprolol dose according to the randomized treatment arm.

DRUGNormal Saline (0.9% NaCl)

Normal saline (0.9% NaCl) will be administered intravenously before anesthetic induction as placebo in a volume matched to the metoprolol intervention. The study drug will be delivered through a dedicated intravenous catheter, and participants assigned to the placebo arm will receive a volume corresponding to the randomized dosing schedule used in the metoprolol groups.

Sponsors

Fujian Provincial Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
TRIPLE (Subject, Caregiver, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No

Inclusion criteria

* Age 18 to 65 years. * American Society of Anesthesiologists physical status I or II. * Scheduled for elective non-cardiac surgery. * Planned general anaesthesia with endotracheal intubation.

Exclusion criteria

* Cardiovascular or respiratory diseases, such as uncontrolled hypertension or bronchial asthma. * Current use of β-blockers. * History of chronic drug use or alcohol abuse. * Hepatic or renal impairment. * Known allergy to any study drug. * Anticipated difficult airway. * Any other condition that may affect the conduct of the study.

Design outcomes

Primary

MeasureTime frame
Percentage of participants achieving hemodynamic stability after tracheal intubationwithin 0-10 min after intubation

Secondary

MeasureTime frame
incidence of bradycardiawithin 0-10 min after intubation
incidence of tachycardiawithin 0-10 min after intubation
incidence of hypotensionwithin 0-10 min after intubation
incidence of hypertensionwithin 0-10 min after intubation

Countries

China

Contacts

CONTACTYanhua Guo
guoyanhua19@126.com+86-18050333902
PRINCIPAL_INVESTIGATORYanhua Guo

Fujian Provincial Hospital

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: May 21, 2026